ClinConnect ClinConnect Logo
Search / Trial NCT06726876

Therapeutic Effect of Manuka Honey Oral Rinse on Fibroblast Growth Factor-21 in Periodontitis Patients Undergoing Hemodialysis

Launched by AIN SHAMS UNIVERSITY · Dec 9, 2024

Trial Information

Current as of July 23, 2025

Recruiting

Keywords

Manuka Honey Fibroblast Growth Factor 21 Periodontitis Hemodialysis

ClinConnect Summary

This clinical trial is looking at whether using a special mouth rinse made with Manuka honey can help people with periodontitis (a serious gum disease) who are also undergoing hemodialysis for kidney failure. People with kidney problems often have worse gum disease, which can lead to inflammation and other health issues. Manuka honey is known for its natural antibacterial and healing properties, and researchers want to see if adding this honey rinse to regular gum treatment can improve gum health and affect a specific protein (called FGF-21) linked to tissue repair and inflammation.

The study is open to adults over 18 who have end-stage kidney disease and are currently on hemodialysis, and who also have gum disease. People who smoke, drink alcohol, have certain other serious illnesses, or are pregnant are not eligible to join. If you participate, you can expect to use the Manuka honey mouth rinse alongside your usual gum care, and the researchers will check how your gums respond over time. This trial aims to find a safe and natural way to support gum health in people with kidney failure, which could improve overall well-being.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Both genders, aged above 18 years.
  • All patients must be clinically diagnosed of ESRD undergoing hemodialysis.
  • All patients must have a periodontal disease.
  • Patients must be able to make reliable decision or communications.
  • Exclusion Criteria:
  • Smoking, Alcohol.
  • Patient with history of any serious illness as malignancy, who undergo kidney transplant.
  • Patients with any autoimmune disease.
  • Vulnerable groups such as pregnant females, prisoners, mentally and physically handicapped individuals.
  • Known hypersensitivity or severe adverse effects to the treatment drugs or to any ingredient of their preparation.

About Ain Shams University

Ain Shams University, established in Cairo, Egypt, is a prestigious higher education institution renowned for its commitment to academic excellence and research innovation. As a clinical trial sponsor, the university leverages its extensive resources and expertise in various medical and scientific disciplines to advance healthcare through rigorous research initiatives. With a focus on ethical practices and adherence to regulatory standards, Ain Shams University aims to contribute to the development of new therapies and improve patient outcomes, fostering collaboration among researchers, healthcare professionals, and industry partners in the pursuit of medical advancements.

Locations

Benha, , Egypt

Banhā, , Egypt

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported